Behavioural well being information analytics firm Holmusk has raised $45 million in a Sequence B funding spherical led by Veradigm, previously Allscripts Healthcare Options. The spherical was additionally joined by its present buyers, Heritas Capital, Well being Catalyst Capital, Novartis, and Northwell Holdings.
WHAT IT’S FOR
The Singapore and New York-based firm will use its new funds to proceed increasing its NeuroBlu database, which has grow to be one of many main sources of real-world medical information for the behavioural well being business.
In the meantime, Veradigm additionally intends to signal a knowledge partnership with Holmusk to deliver its cohorts of behavioural well being and associated de-identified affected person information to Holmusk’s database.
THE LARGER TREND
Over the previous two years, Holmusk established a number of partnerships with hospitals and medical analysis institutes worldwide to assist advance behavioural well being analysis whereas rising its NeuroBlu platform. It has present collaborations in the USA with Otsuka, the College of Texas Well being Science Heart and the Harris Heart for Psychological Well being and IDD, and Metrocare Providers; the Nationwide Healthcare Group and the Institute of Psychological Well being in Singapore; and Charité-College Drugs Berlin in Germany.
In the meantime, Veradigm’s funding in Holmusk comes over every week since its rebranding. It now claims to be “well-positioned” to drive development and serve its markets the place there’s a rising shift from disparate methods in the direction of an interoperable system the place well being information will be “translated into actionable insights and assist the next high quality of care.”
ON THE RECORD
“This funding will allow our workforce to proceed its work in curating and enhancing information as we plan to construct the world’s largest platform for behavioural well being information. We stay laser-focused on this mission as a result of we all know that high quality information results in improved proof, which results in higher well being outcomes,” Holmusk CEO and founder Nawal Roy shared.
“Psychological and behavioural well being is a critical international well being downside that has solely elevated throughout and submit the COVID-19 pandemic. Holmusk has confirmed experience to create the proof wanted to enhance psychological well being,” Rick Poulton, CEO of Veradigm, commented.